Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange, aiming to enhance its global development strategy and strengthen its market position [2] Group 1 - The company aims to leverage international capital market resources and mechanisms to optimize its capital structure [2] - The move is expected to broaden financing channels and improve corporate governance and overall strength [2] - This initiative is part of the company's strategy to enhance brand influence and core competitiveness [2]

中国经济网北京7月31日讯华恒生物（688639.SH）昨晚发布关于筹划公司在香港联合交易所有限公司 上市的提示性公告。 华恒生物为深入推进公司全球化发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借 助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，全面提升公司治理水平和综合 实力，正在筹划发行境外股份（H股）并在香港联合交易所有限公司（以下简称"香港联交所"）上市事 宜（以下简称"本次H股上市"）。公司正与相关中介机构就本次H股上市的具体推进工作进行商讨，相 关细节尚未确定，本次H股上市不会导致公司控股股东和实际控制人发生变化。 华恒生物于2021年4月22日在上交所科创板上市，保荐机构为兴业证券股份有限公司，保荐代表人为黄 超、饶毅杰。华恒生物公开发行募集资金总额为62532.00万元，募集资金净额为55925.88万元。华恒生 物于2021年4月16日披露的招股书显示，公司募集资金5.71亿元，分别用于交替年产2.5万吨丙氨酸、缬 氨酸项目、发酵法丙氨酸5000吨/年技改扩产项目、补充流动资金。 根据中国证券监督管理委员会出具的《关于同意安徽华恒生物科技股份有限公司向特定对象 ...

Group 1 - Huaheng Biological plans to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to advance its globalization strategy and enhance brand influence and core competitiveness [1] - The company aims to optimize its capital structure and broaden financing channels by leveraging international capital market resources [1] - The listing process is subject to board and shareholder approval, as well as regulatory review by the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1] Group 2 - Nossger's ongoing equity dispute is nearing resolution as the Supreme People's Court rejected the retrial application from the plaintiff, Zhong Dafa [2] - The company stated that the lawsuit has not impacted its current or future profits, although it may have affected external reputation and investor confidence [2] Group 3 - East China Pharmaceutical's subsidiary, China-US East, received acceptance for its application for the marketing authorization of Edaravone tablets for treating acute ischemic stroke [3] - If approved, Edaravone tablets will enhance the company's cardiovascular product pipeline and may replace existing injection forms, creating market opportunities [3] Group 4 - Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, following a significant stock price fluctuation [4] - The acquisition is still in the planning stage, with no agreements signed yet, leading to uncertainty regarding its implementation [4] - The company has not identified any insider trading activities among executives or major shareholders during this period [4]

Group 1 - As of July 30, 2025, Huaheng Biological's stock price is 33.77 yuan, down 0.74 yuan or 2.14% from the previous trading day [1] - The trading volume on the same day was 54,947 hands, with a transaction amount of 188 million yuan [1] - Huaheng Biological operates in the chemical products industry, focusing on the research, production, and sales of amino acids and their derivatives, which are widely used in food, pharmaceuticals, and feed sectors [1] Group 2 - The company is planning to issue overseas shares and list on the Hong Kong Stock Exchange, with details yet to be determined [1] - This issuance will not change the company's controlling shareholder or actual controller [1] - As of July 30, 2025, the net outflow of main funds for Huaheng Biological was 6.0878 million yuan, accounting for 0.07% of the circulating market value [1]

证券代码：688639 证券简称：华恒生物 公告编号：2025-030 安徽华恒生物科技股份有限公司 关于筹划公司在香港联合交易所有限公司上市的 科创板股票上市规则》 《境内企业境外发行证券和上市管理试行办法》 《香港联合 交易所有限公司证券上市规则》等相关规定，待确定具体方案后，本次 H 股上市 工作尚需提交公司董事会和股东大会审议，并经中国证券监督管理委员会备案和 香港联交所等监管机构审核。 本次 H 股上市能否通过审议、备案和审核程序并最终实施具有较大不确定性。 公司将依据相关法律法规的规定，根据本次 H 股上市的后续进展情况及时履行信 息披露义务。本次 H 股上市尚存在较大不确定性，敬请广大投资者理性投资，注 意投资风险。 安徽华恒生物科技股份有限公司（以下简称"公司"）为深入推进公司全球 化发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借助国际 资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，全面提升公司 治理水平和综合实力，正在筹划发行境外股份（H 股）并在香港联合交易所有限 公司（以下简称"香港联交所"）上市事宜（以下简称"本次 H 股上市"）。公司 正与相关中介机构就本 ...

Group 1: Company Performance - Ningde Times reported a net profit of 30.5 billion yuan for the first half of the year, representing a year-on-year increase of 33.02% [1] - The company achieved revenue of 178.9 billion yuan, an increase of 7.27% compared to the same period last year [1] - Gross profit reached 44.8 billion yuan, up 14.45% year-on-year, with a gross margin of 25.02%, an increase of 1.57 percentage points from the previous year [1] Group 2: Stock Trading and Suspensions - Shangwei New Materials announced a suspension of trading due to multiple instances of abnormal stock price fluctuations, with the suspension expected to last no more than three trading days [2] - Jinchengzi is planning to acquire 55% of Samit Optoelectronics, leading to a stock suspension for up to ten trading days [3] - Sanchao New Materials is also planning a change in control, resulting in a stock suspension for up to two trading days [6] - Hehua Co. announced a stock suspension due to potential changes in its controlling shareholder [9] Group 3: Major Investments and Projects - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [5] - The company will use its own funds for this investment, with the final amount to be confirmed based on state-approved preliminary design estimates [5] Group 4: Other Corporate Actions - Sunshine Dairy's controlling shareholder sold a total of 1.1452 million shares, accounting for 0.41% of the company's total share capital, without triggering any significant changes in control [4] - Nanjing Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with uncertainty regarding whether it constitutes a major asset restructuring [7]

（原标题：7月30日重要资讯一览） 重要的消息有哪些 1．中共中央政治局7月30日召开会议，会议指出，要持续防范化解重点领域风险。落实好中央城市工作会议精神，高质量开展城市更新。积极稳 妥化解地方政府债务风险，严禁新增隐性债务，有力有序有效推进地方融资平台出清。增强国内资本市场的吸引力和包容性，巩固资本市场回稳 向好势头。 2．财政部社会保障司司长郭阳7月30日在国新办新闻发布会上表示，中央财政将设立共同财政事权转移支付项目"育儿补贴补助资金"，今年初步 安排预算900亿元左右。对于发放国家基础标准补贴所需资金，中央财政按照一定比例对地方予以补助，中央财政总体承担90%。 3．7月30日，外交部发言人郭嘉昆主持例行记者会。在回答有关中美经贸会谈的问题时，郭嘉昆表示，关于此次中美经贸会谈的情况，中方已经 发布了消息。我们希望美方同中方一道，按照两国元首通话达成的重要共识，发挥好中美经贸磋商机制的作用，在平等、尊重、互惠基础上，通 过对话沟通，增进共识、减少误解、加强合作，争取更多双赢成果，共同推动中美关系健康稳定可持续发展。 4．国家发改委向社会公开征求《政府投资基金布局规划和投向工作指引》和《加强政府投资基金 ...

Important Announcements - Company Shouwei New Materials will suspend trading for inspection on July 31, 2025, due to abnormal stock price fluctuations from July 9 to July 30, 2025 [2] - Company XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of the year, a year-on-year increase of 2062.33% [4] - Company Yuntian Lifei has submitted an application for H-share issuance and listing [5] - Company Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Company Hehua Co., Ltd. is planning a change in control, leading to a suspension of trading [10] Financial Performance - Company Dingtong Technology reported a net profit of 115 million yuan for the first half of the year, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Company Jinhai Biological achieved a net profit of 138 million yuan in the first half of the year, a year-on-year increase of 51.52% [13] - Company Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of the year, a year-on-year increase of 3.01% [14] Corporate Actions - Company Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Company Jinchengzi is planning to acquire 55% of the shares of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a suspension of trading [9] - Company San Chao New Materials is also planning a change in control, resulting in a trading suspension [11] Project Investments - Company Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [8]

Group 1: Company Announcements - Upwind New Materials will suspend trading for stock review starting July 31, 2025, due to abnormal price fluctuations from July 9 to July 30, 2025 [2] - XGIMI Technology expects a net profit attributable to shareholders of 88.66 million yuan for the first half of 2025, a year-on-year increase of 2062.33% [4] - CloudWalk Technology has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [5] - Huaheng Biological is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Hehua Co., Ltd. is undergoing a control change process, leading to a stock suspension starting July 31, 2025 [9] Group 2: Financial Performance - DingTong Technology reported a net profit of 115 million yuan for the first half of 2025, a year-on-year increase of 134.06%, with a proposed cash dividend of 2 yuan per 10 shares [7] - Jinhe Biological achieved a net profit of 138 million yuan in the first half of 2025, a year-on-year increase of 51.52% [12] - Hisense Home Appliances reported a net profit of 2.077 billion yuan for the first half of 2025, a year-on-year increase of 3.01% [13] Group 3: Corporate Developments - Nanxin Pharmaceutical is planning to acquire a domestic pharmaceutical technology asset group, but there is significant uncertainty regarding the completion of this acquisition [3] - Jinchengzi is planning to acquire 55% of the equity of Changchun Samit Optoelectronics Technology Co., Ltd., leading to a stock suspension starting July 31, 2025 [8] - SanChao New Materials is also planning a control change, resulting in a stock suspension starting July 31, 2025 [10] Group 4: Industry Developments - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project, with a total construction period of 91 months [8] - Yonghui Supermarket intends to raise no more than 3.992 billion yuan through a private placement to upgrade stores and logistics [8]

北京商报讯（记者丁宁）7月30日晚间，华恒生物（688639）发布公告称，公司为深入推进公司全球化 发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借助国际资本市场的资源与机制优 势，优化资本结构，拓宽多元融资渠道，全面提升公司治理水平和综合实力，正在筹划发行境外股份 （H股）并在香港联交所上市事宜。 （文章来源：北京商报） ...